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Abbreviations used
AIT: Allergen immunotherapy
APC: Allophycocyanin
BAT: Basophil activation test
CFSE: Carboxyfluorescein succinimidyl ester
CLR: C-type lectin receptor
CT: Cycle threshold
DC: Dendritic cell
DC-SIGN: Dendritic cell–specific intercellular adhesion molecule
3–grabbing nonintegrin
DMSO: Dimethyl sulfoxide
EF1a: Elongation factor 1a
FITC: Fluorescein isothiocyanate
FOXP3: Forkhead box P3
hmoDC: Human monocyte-derived dendritic cell
ICOSL: Inducible costimulator ligand
IDO: Indoleamine 2,3-dioxygenase
mDC: Myeloid dendritic cell
N: Native grass pollen Phleum pratense allergens
NF-kB: Nuclear factor kB
P: Mannan-free glutaraldehyde-polymerized allergoids
PAO: Phenylarsine oxide
pDC: Plasmacytoid dendritic cell
PD-L1: Programmed death ligand 1
PE: Phycoerythrin
PM: Glutaraldehyde-polymerized allergoids conjugated to
nonoxidized mannan
PM OX: Oxidized PM
SPT: Skin prick test
Treg: Regulatory T
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SIRVENT ET AL 559ELISAs, and ELISpot assays were performed to assess allergen
capture by human DCs and T-cell responses. BALB/c mice were
immunized with PM, N, or P. Antibody levels, cytokine
production by splenocytes, and splenic forkhead box P3
(FOXP3)1 regulatory T (Treg) cells were quantified.
Experiments with oxidized PM were also performed.
Results: PM displays in vivo hypoallergenicity, induces potent
blocking antibodies, and is captured by human DCs much more
efficiently than N or P by mechanisms depending on mannose
receptor– and dendritic cell–specific intercellular adhesion
molecule 3–grabbing nonintegrin–mediated internalization. PM
endorses human DCs to generate functional FOXP31 Treg cells
through programmed death ligand 1. Immunization of mice
with PM induces a shift to nonallergic responses and increases
the frequency of splenic FOXP31 Treg cells. Mild oxidation
impairs these effects in human subjects and mice,
demonstrating the essential role of preserving the carbohydrate
structure of mannan.
Conclusions: Allergoids conjugated to nonoxidized mannan
represent suitable vaccines for AIT. Our findings might also be of
the utmost relevance to development of therapeutic interventions
in other immune tolerance–related diseases. (J Allergy Clin
Immunol 2016;138:558-67.)
Key words: Allergen immunotherapy, vaccines, neoglycans, allergoids,
mannan, immunomodulation, dendritic cells, regulatory T cells
Allergen immunotherapy (AIT) is currently the only curative
treatment for allergic diseases.1-4 AIT involves administration of
high doses of the causative allergen to induce a state of permanent
tolerance after treatment discontinuation.3,5 AIT induces a very
rapid desensitization of mast cells and basophils, which impairs
systemic anaphylaxis.5,6 Tolerance induction requires generation
of allergen-specific regulatory T (Treg) cells, TH1 cells, or both;
allergen-specific regulatory B cells; decreases of allergen-
specific IgE levels; and increases of blocking IgG and IgA levels.5
Although AIT is effective in many cases, it remains underused
and is estimated to be used in less than 10% of patients with
allergic rhinitis or asthma worldwide.1 This is mainly due to
several important drawbacks, including efficacy and safety
concerns or the long duration of the treatment and low patient
adherence. Alternative routes of vaccination and use of different
hypoallergenic derivatives in combination with biological agents
or novel adjuvants have been assayed to solve some of these
problems; however, the progress in clinical trials is still
moderate.7-9 Therefore there is an urgent need to develop more
effective and safer vaccines.
Dendritic cells (DCs) are indispensable for the development of
allergy or tolerance, and the rational design of vaccines targeting
these cells represents a promising therapeutic alternative.10-12 The
induction of peripheral T-cell tolerance through generation of
allergen-specificTreg cells is essential in the restoration of healthy
immune responses to allergens after successful AIT,2,5,13,14 but
the underlying immunologic mechanisms are not yet fully
understood.15 Pathogen- or commensal-derived molecules and
exogenous signals promote tolerogenic DCs that are able to
induce functional Treg cells by using soluble and surface
molecules, such as TGF-b, IL-10, indoleamine 2,3-dioxygenase
(IDO), and programmed death ligand 1 (PD-L1).15-17
Myeloid C-type lectin receptors (CLRs) are pattern
recognition receptors expressed by DCs that bind glycans in aCa21-dependent manner.18 CLR engagement not only mediates
endocytosis but also cell signaling.19,20 Therefore targeting
myeloid CLRs offers the additional advantage of shaping
immune responses.21,22 Antibody-mediated CLR targeting has
been successfully used to induce immunity or tolerance in
patients with cancer or autoimmune diseases.22-24 Recently,
glycan-based targeting approaches have also gained increasing
attention.25,26 In this regard,mannan is a polysaccharide composed
of mannose residues that can be found in plants, fungi, and yeast
and has been shown to enhance antigen presentation, DC matura-
tion, and immune responses.27-29 The mannose receptor (CD206),
dendritic cell–specific intercellular adhesion molecule 3–grabbing
nonintegrin (DC-SIGN; CD209), and Dectin-2 are the main CLRs
expressed by DCs recognizing mannose-terminated sugars.29,30
Glutaraldehyde-polymerized allergens are hypoallergenic
allergoids that reduce undesired side effects during AIT.3,7
Moreover, allergoids alone or in combination with adjuvants have
shown efficacy in clinical trials, but there is still some
controversy in relation to their immunogenicity.31-34 Here, for the
first time, we show that allergoids coupled to nonoxidized mannan
are novel hypoallergenic vaccines targeting DCs that enhance
allergen uptake and promote healthy T-cell responses to allergens
by generating functional forkhead box P3 (FOXP3)1 Treg cells
through PD-L1 in human subjects. Mild oxidation impairs these
features both in human subjects and mice. We uncover that
preservation of the structural integrity of mannan is essential for
the observed effects, which might well pave the way for the
development of novel immunotherapeutic strategies not only for
allergy but also for other immune tolerance–related diseases.
FIG 1. PM shows enhanced in vivo hypoallergenicity and induces potent blocking antibodies. A, SPT
(n5 12). B, BAT (n5 4). C, Inhibition of serum IgE binding to N-coated plates by blocking antibodies induced
by N (AbN), P (AbP), and PM (AbPM; n5 12). C, Negative control; SI, stimulation index; C1, positive control.
Wilcoxon (Fig 1, A and C) or paired Student t (Fig 1, B) tests: **P < .01, ***P < .001, and ****P < .0001.
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Defatted grass pollen grains from P pratense (Iberpolen, Jaen, Spain) were
extracted overnight with PBS (pH 7.2) and subjected to tangential flow
ultrafiltration (cutoff pore size, 100 kDa). The enriched native grass pollen
Ppratense allergens (N) contained in the filtratewere dialyzedwith distilledwater
and lyophilized until use. Total protein content was measured by using the
Bradford assay with serum albumin as the standard (Bio-Rad Laboratories,
Hercules, Calif). The native mannan (nonoxidized) was purified from the yeast
Saccharomyces cerevisiae (Lesaffre, Marcq-en-Baroeul, France), according to
previously described protocols with slight modifications.35,36 N were
polymerized and conjugated with mannan through the lysine residues from its
mannoprotein, as previously described.37,38 Briefly, glutaraldehyde (25 mmol/L)
was added to a solution containing amixture of allergen andmannan (1:0.5wt/wt)
in PBS for 6 hours at 48C in continuous stirring. The reaction was stopped with
glycine (1.25 mol/L), followed by tangential flow filtration with distilled water
(membrane cutoff, 100 kDa). Glutaraldehyde-polymerized allergoids conjugated
to nonoxidizedmannan (PM)were recovered in the concentrated retained fraction
(>100 kDa). Stable allergen-mannan conjugates were confirmed by means of
nuclear magnetic resonance, including 2 Dimensional-Difussion Ordered Spec-
trocopY (2D-DOSY) and 1H-13C Heteronuclear Single Quantum Correlation
(HSQC) spectra.37,38 The same native allergen extract was subjected to the above
protocol but without mannan to obtain mannan-free glutaraldehyde-polymerized
allergoids (P). For some experiments, PM was treated with sodium periodate
(5 mmol/L) at 48C for 1 hour with continuous stirring in the dark. The reaction
was stopped with ethylene glycol (1.8 mol/L), dialyzed against distillated water,
and lyophilized to obtain oxidized PM (PM OX). PM oxidation was monitored
and assessed by using 1-dimensional nuclear magnetic resonance spectra.38
The study was approved by the Regional Ethics Committee of Comunidad
Autonoma deMadrid (EudraCT: 2014-005471-88). Written informed consent
was obtained from all subjects. The general clinical characteristics of the 12
patients with grass pollen allergy included in this study are summarized in
Table E1 in this article’s Online Repository at www.jacionline.org. Animal
experiments were approved by the Ethics Committee of Hospital Clınico
San Carlos and performed in accordance with the Spanish national and
international/EU legislation regulated by D.C.86/609/CEE; RD 1201/2005.
All procedures are fully described in the Methods section in this article’s
Online Repository at www.jacionline.org.RESULTS
Allergoids conjugated to nonoxidized mannan
shows increased in vivo hypoallergenicity and
induces potent blocking antibodies
We hypothesized that coupling mannan to allergoids would
significantly enhance their allergen uptake by DCs and promotetolerance while retaining hypoallergenicity. As a proof of
concept, we generated novel grass pollen vaccines by
coupling mannan from the cell wall of the yeast S cerevisiae to
allergen-enriched P pratense pollen extracts in the presence of
glutaraldehyde without prior sugar oxidation (see Fig E1 in this
article’s Online Repository at www.jacionline.org). This strategy
generates stable neoglycans of polymerized allergens (allergoids)
conjugated with nonoxidized mannan (ie, PM) with low in vitro
IgE-binding reactivity.37,38 The in vivo hypoallergenic character
of PM was assessed and compared with the same batch of native
(N) and glutaraldehyde-polymerized (P) allergen-enriched
P pratense pollen extracts by using skin prick tests (SPTs) in
patients with well-defined grass pollen allergy. The capacity of
PM to induce IgE cross-linking in skin mast cells was
significantly lower than that of N and P (Fig 1, A). Ex vivo
basophil activation tests (BATs) showed that PM and P display
a similar reduced capacity to activate basophils from patients
with grass pollen allergy than seen with N (Fig 1, B).
Immunization of rabbits with PM induced potent allergen-
specific blocking antibodies able to inhibit the IgE binding of
sera from patients with grass pollen allergy to N more efficiently
than those induced by P and with similar effectiveness than those
induced by N (Fig 1, C).Allergoids conjugated to nonoxidized mannan
target CLRs and are captured more efficiently by
human DCs than conventional allergoids and native
allergens
Freshly prepared human monocyte-derived dendritic cells
(hmoDCs) displayed an immature phenotype and expressed
significant levels of the mannose receptor (CD206), DC-SIGN
(CD209), and Dectin-2 (see Fig E2, A, in this article’s Online
Repository at www.jacionline.org). N, P, and PM were equally
labeled with specific fluorophores when using sulfhydryl but
not amino-reactive probes (see Fig E2, B). Kinetic uptake
experiments monitored by means of flow cytometry with equally
fluorescence-labeled N, P, and PM revealed that PM is captured
by hmoDCs much more efficiently than P and N at all assay times
(Fig 2, A). Representative dot plots and confocal microscopic
images of the internalization of the different extracts after
FIG 2. PM is captured much more efficiently by human DCs than N or P by targeting CLRs. A, Timing of
fluorescence-labeled N, P, and PM allergen uptake by hmoDCs (n5 5). B, Representative flow cytometric plots
and confocal images. C and D, Inhibition of the capture of fluorescence-labeled PM with the indicated com-
pounds (Fig 2, C) or blocking antibodies or EDTA related to vehicle or isotype control (Fig 2, D; n 5 4).
E, Representative confocal images. Fluorescence-labeled allergens (green), HLA-DR (red), and 49-6-diamidino-
2-phenylindole dihydrochloride (blue). Values are means6 SEMs. Paired Student t test: *P < .05 and **P < .01.
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uptake inhibition experiments using cytochalasin D, chlorproma-
zine, or phenylarsine oxide (PAO). Around 45% of the PM uptake
was inhibited by PAO, indicating that the process is highly
dependent on receptor-mediated internalization mechanisms
(Fig 2, C). To identify which CLRs were involved in taking up
PM, we used specific blocking antibodies for mannose receptor
(CD206), DC-SIGN (CD209), or Dectin-2. EDTA inhibited
around 39% of the capture of PM, and blocking the 3 CLRs
simultaneously reached an inhibition of around 32% (Fig 2, D).
Mannose receptor (26%) and DC-SIGN (16%) were the main
CLRs contributing to the PM uptake by hmoDCs (Fig 2,D andE).Human DCs stimulated with PM increase PD-L1
expression and produce IL-6 and IL-10 through
mechanisms depending on CLR-mediated
activation of nuclear factor kB
We treated hmoDCs with N, P, and PM and studied the
expression pattern of different surface molecules and cytokineproduction. hmoDCs stimulated with N, P, or PM expressed
comparable high levels of HLA-DR and CD86 as expected for
DCs with no expression of inducible costimulator ligand (ICOSL;
Fig 3, A). CD83 expression was significantly higher in P- and
PM-treated than N-treated hmoDCs, with lower levels induced
by PM than P (Fig 3, A). PM treatment significantly increased
expression of the inhibitory molecule PD-L1 compared with N
and P both at the protein and mRNA levels (Fig 3, A, and see
Fig E3 in this article’s Online Repository at www.jacionline.
org), suggesting that PM is able to induce a more tolerogenic
phenotype on DCs. We also analyzed the expression pattern of
the IDO, retinaldehyde dehydrogenase (RALDH), and suppressor
of cytokine signaling (SOCS) genes at the mRNA level and did
not find significant differences in expression of these molecules
(see Fig E3). PM-treated hmoDCs produced significantly
higher levels of IL-6 and IL-10 and lower IL-4 levels than N- or
P-treated hmoDCs (Fig 3, B). We did not detect production of
IL-12 in any case and detected very low levels of IL-23 only
after N stimulation (Fig 3, B). Experiments with specific blocking
antibodies showed that mannose receptor (CD206) and Dectin-2
FIG 3. PM immunomodulates the phenotype and function of hmoDCs. A and B, Flow cytometric DMFI
(mean fluorescence intensity after isotype control subtraction, n 5 9; Fig 3, A) or cytokine production
(n 5 7; Fig 3, B) after stimulation of hmoDCs with N, P, and PM for 18 hours. C, Inhibition of the
PM-induced PD-L1 expression in hmoDCs by indicated blocking antibodies related to MFI values with
isotype controls (n 5 4). D, Inhibition of IL-6 and IL-10 or increase in IL-4 production by PM-activated
hmoDCs by blocking antibodies related to isotype controls (n 5 4). E, Western blot analysis of protein
extracts from N-, P-, or PM-activated hmoDCs (30 minutes of incubation) and quantification of reactive
bands (n 5 3). F, Expression of PD-L1 and cytokine production by PM-activated hmoDCs without or with
BAY-117082 (n 5 8). *P < .05, **P < .01, and ***P < .001.
FIG 4. PM immunomodulates the phenotype and function of human mDCs and pDCs. A, Dot plots of
different DC subsets in PBMCs and the total DC fraction. B, DMFI (after isotype control subtraction) of
PD-L1 on HLA-DR1CD1c1CD3032 mDCs and HLA-DR1CD1c2CD3031 pDCs from the total DC fraction
stimulated with N, P, or PM. C-E, Cytokines after stimulation of total blood DCs (Fig 4, C), enriched mDCs
(Fig 4, D), or enriched pDCs (Fig 4, E) with N, P, and PM for 18 hours (mean 6 SEM, n 5 4). Paired Student
t test: *P < .05 and **P < .01.
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CD206, DC-SIGN, and Dectin-2 contributed at different extents
to the observed effects at the cytokine level (Fig 3, D). Purified
mannan also produced significant IL-6 and IL-10 levels (data
not shown), suggesting that the capacity of PM to induce the
production of these cytokines by DCs is likely due to the
incorporation of mannan to the allergoid. The activation of
nuclear factor kB (NF-kB) was significantly higher after
stimulation with PM thanN or P (Fig 3,E), and the pharmacologic
inhibition of this transcription factor significantly reduced
PM-induced PD-L1 expression, abolished IL-6 and IL-10
production, and increased IL-4 levels (Fig 3, F).From peripheral blood, we isolated a human DC fraction
containing myeloid dendritic cells (mDCs) and plasmacytoid
dendritic cells (pDCs; Fig 4, A). Both mDCs and pDCs activated
with PM also showed higher expression PD-L1 than DCs
activated with N or P (Fig 4, B). The total human blood DC
fraction activated with PM also produced significantly higher
IL-6 and IL-10 levels and lower IL-4 levels than seen after
activated with N or P (Fig 4,C). Interestingly, the IL-10/IL-4 ratio
was also significantly higher when human DCs were
activated with PM than with N or P (Fig 4, C), thus
confirming the results obtained for hmoDCs. PM-activated
mDCs produced significantly higher levels of IL-6 and IL-10
FIG 5. PM promotes the generation of healthy responses to allergens in human subjects. A, Cytokines
produced by allogeneic naive CD41 T cells primed by N-, P-, or PM-activated hmoDCs after 5 days
(n 5 6). B, ELISpot analysis of allergen-specific cytokine-producing T cells after in vitro expansion of naive
and memory T cells primed with autologous N-, P-, or PM-activated DCs (n 5 14). SFC, Spot-forming cells.
C, Cytokines produced by PBMCs from allergic donors (n 5 6) after activation with N, P, or PM for 5 days.
Values are means 6 SEMs. Paired Student t test: *P < .05, **P < .01, and ***P < .001.
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IL-4 detected in any case (Fig 4, D). PM-activated pDCs also
produced significantly higher levels of IL-6 than N- or P-activated
pDCs, but they did not produce substantial levels of IL-10 or IL-4
(Fig 4, E).Allergoids conjugated to nonoxidized mannan
promote the generation of functional FOXP31 Treg
cells through PD-L1 in human subjects
To study the capacity of human DCs activated with PM to
polarize T-cell responses, we performed coculture experiments.
N-, P-, and PM-treated hmoDCs induced proliferation of
allogeneic naive CD41 T cells in a similar manner (see Fig E4
in this article’s Online Repository at www.jacionline.org).
PM-treated hmoDCs generated T cells producing significantlyhigher IFN-g and IL-10 levels and lower IL-5 levels than
T cells primed by N- or P-treated hmoDCs (Fig 5, A).
There was no significant production of IL-17 in any case. The
IL-10/IL-5 ratio was significantly higher when T cells were
generated by hmoDCs activated with PM than with N or P
(Fig 5, A). These data, together with IFN-g levels, suggest that
PM-activated hmoDCs promote the generation of TH1 cells and
a TH2/Treg cell shift in favor of Treg cells (Fig 5, A). Supporting
these results, the same T-cell profile was observed by using
ELISpot analysis when naive and memory T cells were primed
by N-, P-, or PM-treated hmoDCs with ex vivo immunization
protocols in an antigen-specific manner (Fig 5, B). Interestingly,
and in line with these data, the IL-5/IFN-g ratio was significantly
lower when PBMCs from allergic patients were stimulated with
PM than with N or P (Fig 5, C). In contrast, the IL-10/IL-5 ratio
was increased after PM stimulation (Fig 5, C).
FIG 6. PM promotes the generation of functional FOXP31 Treg cells through PD-L1 in human subjects.
A, Percentage of induced CD41CD25highCD1272FOXP31 Treg cells by allogeneic N-, P-, and PM-treated
hmoDCs after 5 days (lymph gate, n 5 4). B, Proliferation of CFSE-labeled PBMCs gated on CD41 cells after
5 days of coculture with autologous purified FOXP31 Treg cells induced by allogeneic N-, P-, or
PM-activated hmoDCs (ratio 1:1). The percentage of proliferating responder PBMCs stimulated with
plate-bound anti-CD3 and soluble anti-CD28 for each condition at a 1:1 ratio is shown (n 5 3).
C, CD41CD25highCD1272FOXP31 Treg cells generated by allogeneic PM-treated hmoDCs in the presence
of isotype control or PD-L1 blocking antibodies (n 5 5). D, Suppressive capacity of Treg cells induced by
PM-treated hmoDCs when inhibiting PD-L1. Percentage of proliferating responder PBMCs stimulated
with plate-bound anti-CD3 and anti-CD28 for each condition (1:1 ratio). One of 4 representative examples
is shown. E, Cytokines produced by allogeneic naive CD41 T cells cocultured with PM-treated hmoDCs
for 5 days in the presence of isotype control or PD-L1 blocking antibodies added at the beginning of
coculture (n 5 9). Values are means 6 SEMs. Paired Student t test: *P < .05, **P < .01, and ***P < .001.
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DCs to induce Treg cells, we performed allogeneic coculture
experiments and analyzed the generation of FOXP31 Treg cells.
Human monocyte-derived DCs treated with PM induced
significantly higher numbers of CD41CD25highCD1272FOXP31
Treg cells than N- or P-treated hmoDCs (Fig 6, A). The FOXP31
Treg cells generated by PM-treated hmoDCs inhibited the
proliferation of autologous PBMCs in a dose-dependent
manner (see Fig E5 in this article’s Online Repository at
www.jacionline.org) and showed a slight but significantly more
potent suppression capacity than those generated by N- or
P-treated hmoDCs when assayed at a Treg cell/PBMC ratio of
1:1 (Fig 6, B). The generation of functional FOXP31 Treg cells
by PM-treated hmoDCs was significantly reduced when blocking
PD-L1 (Fig 6, C), and the remaining FOXP31 Treg cells
showed reduced capacity to inhibit proliferative responses,
as demonstrated by using conventional suppression assays
(Fig 6, D). PD-L1 blocking also significantly enhanced cytokine
production of the T cells generated by PM-activated hmoDCs and
reduced IL-10/IL-5 ratio (Fig 6, E).Oxidation of mannan impairs the capture of PM by
human DCs and tolerogenic properties both in
human subjects and mice
To assess the role of keeping the structural integrity of mannan
after conjugation to allergoids in the observed effects, we
subjected fluorescence-labeled PM to mild oxidation (PM OX)
without affecting the intensity of fluorescence emission (data not
shown) and compared the ability of hmoDCs to internalize PMand PM OX by using flow cytometry and confocal microscopy.
The oxidation process destroyed the mannan structure as
monitored by 1-H nuclear magnetic resonance (NMR) studies
(see Fig E6 in this article’s Online Repository at www.jacionline.
org). Oxidation of PM significantly reduced the capacity of
hmoDCs to internalize the glycoconjugate after 30 and 60minutes
of incubation (Fig 7, A). Representative dot plots and confocal
images are displayed (Fig 7, B). Similarly, oxidation significantly
inhibited PD-L1 expression induced by PM in hmoDCs (Fig 7,C).
PMOX–activated hmoDCs produced significantly lower IL-6 and
IL-10 levels and higher IL-4 levels than PM-activated hmoDCs
(Fig 7, D). As shown in Fig 7, the IL-10/IL-4 ratio was also
significantly reduced after PM oxidation. The percentage of
generated CD41CD25highCD1272FOXP31 Treg cells in
allogeneic cocultures was significantly reduced when hmoDCs
were activated with PM OX compared with PM (Fig 7, E).
To assess the in vivo relevance of these findings, we immunized
subcutaneously BALB/c mice with N, P, PM, or PM OX and
analyzed the induction of CD41CD25highFOXP31 Treg cells in
the spleen. The percentage of CD41CD25highFOXP31 Treg
cells (gated as shown in Fig E7 in this article’s Online
Repository at www.jacionline.org) was significantly higher in
splenocytes from mice immunized with PM than with N or P,
and oxidation of PM significantly abolished this increment
(Fig 7, F). The ratio of serum IgG2a/IgE levels specific for native
grass pollen extract was significantly higher in mice
immunized with PM than in those immunized with N or P, and
oxidation of PM also abolished this increment (Fig 7, G). In
the same way the IL-10/IL-4 ratio after in vitro stimulation
with native grass pollen extract was significantly higher in
FIG 7. Capacity of PM to promote healthy immune responses to allergens depends on keeping the structure
of nonoxidized mannan in the generated conjugate. A,Uptake of fluorescence-labeled PM or PM previously
subjected to oxidation (PM OX) after 30 or 60 minutes of incubation with hmoDCs. B, Dot plots and confocal
images after 60 minutes. PM/PM OX (green), HLA-DR (red), and 49-6-diamidino-2-phenylindole
dihydrochloride (blue) are shown. C, PD-L1 expression on hmoDCs treated with PM or PM OX for 18 hours.
DMFI after isotype control subtraction is shown. D, Cytokines produced by hmoDCs stimulated with PM or
PM OX for 18 hours. E, Percentage of CD41CD25highCD1272FOXP31 Treg cells generated by allogeneic PM-
or PMOX–treated hmoDCs after 5 days. F, Percentage of CD41CD25highFOXP31 Treg cells in spleens of mice
immunized with N, P, PM, or PM OX. Representative dot plots are shown. G, Ratio of serum grass
pollen–specific IgG2a/IgE from mice immunized with N, P, PM, and PM OX. H, IL-10/IL-4 ratio produced
by splenocytes from mice immunized with N, P, PM, or PM OX after in vitro stimulation with N. Values
are means 6 SEMs of 3 (Fig 7, A) or 5 (Fig 7, C-E). For Fig 7, F-H, n 5 5 individual mice per condition of 1
of 3 independent experiments. The paired Student t test was used for Fig 7, A-E, and the unpaired Student
t test was used for Fig 7, F-H: *P < .05, **P < .01, and ***P < .001.
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increment was impaired when PM was subjected to oxidation
(Fig 7, H).DISCUSSION
In this study we have provided evidence that allergoids coupled
to native mannan (nonoxidized) represent novel suitable
preparations to formulate improved vaccines for AIT. PM
displays in vivo hypoallergenicity, induces potent blocking
antibodies in rabbits, is captured by human DCs much more
efficiently than N or P, and endorses cells with the capacity to
generate functional FOXP31 Treg cells through PD-L1. In mice
immunization with PM also increases the frequency of splenic
FOXP31 Treg cells and induces a shift to nonallergic responses.
Mild oxidation impairs these effects in both human subjects and
mice, indicating that preservation of the carbohydrate structure
of mannan during conjugation is essential for the reported
features. This study shed light into the basic structural and
immunologic mechanisms that place allergoids conjugated to
nonoxidize mannan as suitable vaccines for AIT.
AIT represents the only treatment for allergy with the capacity
to modify the course of the disease1,2; however, it still faces
several drawbacks in terms of efficacy, security, duration, andpatient compliance, and therefore novel vaccines that overcome
such inconveniences are in demand.7,9 Mannan from S cerevisiae
can be conjugated with allergens under nonoxidizing
conditions by using glutaraldehyde, which results in very stable
mannan-allergoid complexes, as detected by using nuclear
magnetic resonance.37,38 Here we have performed a detailed
immunologic study of PM in comparison with N and P to validate
the suitability of this conjugate as novel vaccines for AIT before
clinical translation.
Immunization of rabbits with PM induced potent blocking
antibodies to the nominal native allergen, which is a key feature
for successful AIT.39-41 PM is captured by human DCs
much more rapidly and efficiently than N or P through
mechanisms mainly depending on mannose receptor– and
DC-SIGN–mediated endocytosis. This enhanced allergen uptake
could help increase the effective dose of the vaccine without
increasing its allergen concentration, which, together with the
higher in vivo hypoallergenicity showed by PM, might well
contribute to the design of efficacious, shorter, and safer
immunotherapy protocols.9,32,42,43
Human DCs activated with PM produce high levels of IL-10
and significantly increase the expression of PD-L1, which are
molecules involved in the generation of different types of
functional Treg cells.5,14,44-46 Our data indicate that both mDCs
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produce IL-10 after PM stimulation. The expression of PD-L1
on DCs has been demonstrated to be linked to their capacity to
induce functional FOXP31 Treg cells both in mice and human
subjects.45-48 In mice PD-L1 promotes functional FOXP31
Treg cells during tolerance induction to allergens associated
with changes in lung microbiota of neonates.45 In human subjects
Staphylococcus aureus converts neonatal conventional CD41
T cells into FOXP31 Treg cells through the PD-1/PD-L1 axis.46
The bacterial components directly involved in such processes
were not investigated in any of these studies. Herein we show
that PM is able to significantly increase the expression of
PD-L1 on human DCs and promote the generation of functional
FOXP31Treg cells onlywhen the structural integrity of the native
mannan (ie, nonoxidized) is retained. PM-induced PD-L1
expression on DCs required signaling through mannose receptor
and DC-SIGN, leading to NF-kB activation. Blocking of PD-L1
impairs the generation of functional FOXP31 Treg cells,
enhances the production of T-cell effector cytokines, and
significantly decreases the IL-10/IL-5 ratio. It has been previously
shown that PD-L1 ligation impedes the T-cell receptor signaling
pathway, which can lead to differentiation into FOXP31 Treg
cells.47-50 In line with our results, compelling experimental
evidence has also demonstrated that under certain circumstances,
fully mature DCs might also promote the generation of Treg
cells.51-53 Interestingly, we show that mice immunized with PM
also display significantly larger numbers of splenic FOXP31
Treg cells and higher IL-10/IL-4 ratios than those immunized
with N or P. The ratio of serum allergen-specific IgG2a/IgE levels
was significantly higher in PM-immunized mice than in N- or
P-immunized mice, indicating that PM promotes in vivo healthy
immune responses to allergens.
Importantly, our data uncover that keeping the integrity of the
mannan structure is essential for the reported immunologic
properties of PM, which also might be of great relevance when
designing glycan-based targeting strategies for other different
therapeutic interventions.18,25,29 Oxidation leads to the structural
disruption of mannan, which might condition functional
properties.54 For example, immunization with MUC1 coupled
to oxidized mannan or to oxidized and subsequently reduced
mannan promoted differential immune responses in mice. Only
mice immunized with oxidized mannan-MUC1 induced potent
tumor-specific CD81 T-cell responses.55,56 Recently, targeting
antigens to Mannose receptor by coupling them to oxidized
mannan has been shown to suppress pathogenic autoimmune
responses through expansion of anergic antigen-specific TH1
and TH17 cells without generating Treg cells.
57 In this
experimental model PD-L1 expression was downregulated on
DCs by oxidized mannan.57 Hypoallergenic neoglycoconjugates
created by coupling allergens to oxidized mannan were reported
to enhance immunogenicity, but their tolerance induction
capacity was not assessed.58 In contrast to these approaches,
our method of conjugation avoids initial sugar oxidation and
retains the integrity of the mannan structure in PM, which seems
to be essential for the observed immunogenicity and tolerogenic
capacity. In this study we used grass pollen allergens as a proof
of concept, but the same allergen uptake and immunomodulatory
properties have been observed when coupling nonoxidized
mannan to other relevant allergenic sources, such as house dust
mites or different tree pollens (data not shown), according to
this innovative method of conjugation. Interestingly, BSAcoupled to individual mannose molecules without prior sugar
oxidation was shown to induce oral tolerance in a food allergy
mouse model by targeting lamina propria DCs through SIGNR1,
the mouse homologue for human DC-SIGN.44 These DCs
generated type 1 IL-10–producing but not FOXP31 Treg cells.
These data support that the structural integrity of mannoses might
be a requisite to generate Treg cells. The differences observed in
this type of induced Treg cell might be justified not only by the
different experimental system but also because we coupled the
whole mannan polysaccharide to allergoids instead of single
mannose residues to purified BSA, which results in very different
molecular entities. Recognition by different CLRs is highly
dependent on the carbohydrate branching, spacing, and
multivalency.18,25 Our data show that PM can simultaneously
target mannose receptor, DC-SIGN, and Dectin-2, which
contribute to different extents to each of the reported functional
outcomes after global integration of the induced signaling
pathways. The strength and duration of signaling and induced
functional response not only depend on the type of targeted
CLR but also on specific features of the ligand, such as low or
high affinity, soluble or particulated, and particle size.18-20
In summary, for the first time, we have demonstrated that
allergoids coupled to mannan through a method that avoids sugar
oxidation might well represent novel hypoallergenic vaccines for
AIT, which enhance allergen uptake and promote the generation
of functional FOXP31 Treg cells through PD-L1 in human
subjects. These findings might be of the utmost importance for
the development of alternative therapeutic interventions for other
immune tolerance–related diseases.
Clinical implications: Glutaraldehyde-polymerized allergoids
coupled to native nonoxidized mannan represent novel suitable
preparations to formulate vaccines that might well help in the
design of efficacious, shorter, and safer AIT protocols.REFERENCES
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Material, media, and reagents
The medium used for cell cultures was RPMI 1640 (Lonza, Basel,
Switzerland) supplemented with 10% heat-inactivated FBS (Gibco, Grand
Island, NY), antibiotics (penicillin and streptomycin; Life Technologies,
Grand Island, NY), MEMVitamin Solution, L-glutamine, nonessential amino
acids, sodium pyruvate (Life Technologies, Grand Island, NY), and Normocin
(InvivoGen, San Diego, Calif). Flow cytometric antibodies were purchased
from Miltenyi Biotec (Bergisch Gladbach, Germany; human anti–HLA-
DR–fluorescein isothiocyanate [FITC], anti–HLA-DR–allophycocyanin
[APC], anti-CD83–APC, anti-CD86–phycoerythrin [PE], anti-CD303–PE,
anti-CD1c–FITC, anti-CD127–PE, anti-CD4–APC, anti-CD25–peridinin
chlorophyll protein complex [PerCP], anti-CD206–APC, anti-CD209–PE
[FcR Blocking]); BioLegend (San Diego, Calif; human anti-FOXP3–Alexa
Fluor 488, mouse anti-FOXP3–Alexa Fluor 488, mouse anti-CD4–PerCP,
and mouse anti-CD25–PE), and BD PharMingen (San Jose, Calif; human
anti-PD-L1–FITC and human anti-ICOSL–PE). Blocking antibodies were
anti-CD206 (clone 15-2, BioLegend), anti-CD209 (clone 120507; R&D
Systems, Minneapolis, Minn), anti–Dectin-2 (clone 545943, R&D Systems),
and anti–PD-L1 (clone 29E.2A3, BioLegend) and corresponding isotype
controls. None of the reagents contained detectable amounts of LPS, as deter-
mined by using the Limulus assay (Cambrex Bio Science, Walkersville, Md).
SPTs and BATs
SPTs were performed with N, P, or PM in 12 patients with well-defined
grass pollen allergy in accordance to standard procedures.E1 Each patient was
simultaneously tested by duplicates with the 3 different preparations (N, P, and
PM) by using the Prick-Film technology (Inmunotek, Madrid, Spain) by the
same operator. Histamine dihydrochloride and physiologic saline solutions
were used as positive and negative controls, respectively. Results of SPTs
were automatically processed and quantified by using planimetry with the
proper software (Prick-Film) and expressed as median wheal size in square
millimeters. A wheal area of less than 7 mm2 was considered negative.
BATs were performed with N, P, and PM extracts by using heparinized whole
blood from 4 patients with well-defined grass pollen allergy and the BasoTest
(ORPEGEN Pharma, Baden-Wurttemberg, Germany). Anti-human IgE
antibodies (BD PharMingen) and physiologic saline solutions were used as
positive and negative controls, respectively. Stimulation indexes were
calculated as the ratio between the percentage of activated basophils with
the stimulus and the negative control. The study was approved by the
Regional Ethics Committee of Comunidad Autonoma de Madrid
(EudraCT:2014-005471-88). Written informed consent was obtained from
all subjects.
ELISA inhibition of the binding of serum IgE from
allergic patients to N extract by blocking antibodies
induced after immunization of rabbits with N, P,
or PM
New Zealand rabbits were immunized subcutaneously with 0.5 mg of N, P,
or PMmixedwith complete Freund adjuvant. The rabbits were given 3 booster
doses with incomplete Freund adjuvant at 14-day intervals. After 2 weeks
from the last immunization, rabbits were bled to collect whole blood from the
carotid artery. The blocking capacity of the serum antibodies generated by
means of immunization of rabbits with N, P, and PM was analyzed by
using ELISA inhibition assays, as previously described,E2 with minor
modifications. Microtiter plates (Corning Inc, Corning, NY) were coated
with 100mL/well of N (5mg/mL) overnight at 48C. Plates werewashed 3 times
with PBS and 0.1% vol/vol Tween-20 and blocked for 1 hour with PBS, 0.1%
vol/vol Tween-20, and 3% wt/vol dehydrated milk. Then plates were
incubated with rabbit serum immunized against N, P, and PM extracts diluted
1:50 in PBS, 0.1% vol/vol Tween-20, and 3% wt/vol dehydrated milk.
After 1 hour of incubation, plates were washed 4 times with PBS and 0.1%
vol/vol Tween-20 and incubated for 2 hours with individual serum from
10 patients with well-defined grass pollen allergy diluted 1:10 in PBS, 0.1%
vol/vol Tween-20, and 3% wt/vol dehydrated milk. After 4 washes, boundIgE antibodies were detected by incubating with mouse anti-human IgE
antibodies (1:5000 diluted), followed by horseradish peroxidase–coupled
goat anti-mouse IgG (diluted 1:2500; Dako, Glostrup, Denmark). The
peroxidase reaction was developed by using fresh enzyme substrate (0.03%
H2O2 and 0.63 mg/mL o-phenylenediamine in 0.1 mol/L sodium citrate, pH
5.0), and the reaction was stopped with 3 N H2SO4. OD was measured at
492 nm in an ELISA reader. Each OD value was the mean of 2 determinations
after blank subtraction.
Flow cytometry and confocal microscopy
Labeling of cell-surface markers was performed at room temperature for
15 minutes in PBS, 2 mmol/L EDTA, and 0.5% BSA. Cells were then washed
with PBS, 2 mmol/L EDTA, and 0.5%BSA and resuspended in PBS and 0.1%
paraformaldehyde. For analysis of FOXP3 expression in humanT cells primed
with DCs, cells were first subjected to surface staining with anti-human
CD4-PerCP, CD127-PE, and CD25-APC (Miltenyi Biotec). After fixation and
permeabilization, cells were stained with anti-human FOXP3–Alexa Fluor
488 (BioLegend), according to the manufacturer’s recommendations. The
same protocol described above was carried out for the phenotypic
characterization of CD41CD25highFOXP31 Treg cells in freshly isolated
mouse splenocytes using anti-mouse CD4-PerCP and CD25-PE antibodies
for surface staining and anti-mouse FOXP3–Alexa Fluor 488 (BioLegend)
for intranuclear staining. The corresponding isotype controls were included
in all stainings. Flow cytometric analysis was performed with a FACSCalibur
cytometer (Becton Dickinson) and further by usingWeasel v2.5 software. For
confocal microscopy, stained cells were subjected to cytospin (600g for
8 minutes), fixed with ice-cold methanol for 5 minutes, and stained with
ProLong Gold–DAPI (Dako) 24 hours before analysis. Images were acquired
and analyzed by using the confocal microscope Leica SP-2 AOBS (Leica,
Wetzlar, Germany).
Differentiation of hmoDCs and isolation of total DC
fraction from human PBMCs
PBMCs from healthy donors were isolated by using Ficoll-Paque Plus (GE
Healthcare, Fairfield, Conn) density gradient centrifugation from heparinized
blood. Monocytes were isolated from PBMCs with anti-human CD14
microbeads (Miltenyi Biotec) by using positive magnetic selection in
autoMACS (Miltenyi Biotec), according to the manufacturer’s
recommendations. Purified monocytes were cultured in RPMI with
recombinant human GM-CSF and IL-4 (100 ng/mL each; PeproTech, Rocky
Hill, NJ). After 6 days of culture, immature hmoDCs were harvested, and the
expression of specific surface markers was analyzed by means of flow
cytometry for phenotype determination. The total DC fraction was obtained
from PBMCs with the Blood Dendritic Cell Isolation Kit II (Miltenyi Biotec),
according to the manufacturer’s protocol. The presence and content of mDC
and pDC subsets within the obtained total DC fraction was analyzed by using
flow cytometry with anti-human CD1c-FITC, CD303-PE, CD19-PEyC7, and
HLA-DR–APC (Miltenyi Biotec). An enriched fraction of mDCs and pDCs
was obtained from peripheral blood by using the CD1c (BDCA-1)1 and
CD304 (BDCA-4/Neuropilin-1) DC isolation kits, respectively (Miltenyi
Biotec), as previously described with minor modifications.E3 In all cases
cell viability was routinely checked by using trypan blue cell exclusion in
the light microscope and/or YO-PRO/propidium iodide staining and flow
cytometric analysis. N, P, or PM did not show toxicity on DCs at the
concentrations used, and significant differences in cell viability were not
detected for all the assayed conditions.
Fluorescent labeling of N, P, and PM
N, P, and PM allergen extracts were labeled with Alexa Fluor 488 dye
conjugated with a thiol-reactive group (Alexa Fluor 488 C5 maleimide, Life
Technologies) or with an amine-reactive group (Alexa Fluor 488 succinimidyl
ester, Life Technologies), according to themanufacturer’s instructions. For the
thiol-reactive probe labeling, extracts dissolved in PBS (5 mg/mL) were
incubated for 15 minutes with 25 mmol/L Tris(2-carboxyethyl) phophine
(TCEP) in a nitrogen atmosphere. One hundred micrograms of Alexa Fluor
488 C5 maleimide dissolved in dimethyl sulfoxide (DMSO; 2 mg/mL) was
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dark, the reaction was stopped by adding 20 mL of b-mercaptoethanol and
maintaining stirring for 15 minutes. Uncoupled free Alexa Fluor 488 was
removed by means of gel filtration with a PD-10 column with PBS. The
fluorescence-labeled allergens were concentrated with Nanosep 3K Omega
(Pall Corporation, Port Washington, NY), and the degree of labeling was
checked with the FLUOstar OPTIMAfluorescence reader (BMGLabtech, Or-
tenberg, Germany). Labeling of allergens with Alexa Fluor 488 succinimidyl
ester probes according to the manufacturer’s indications did not render final
products with equal degree of fluorescence because of the lack of free lysine
residues during polymerization with glutaraldehyde in P and PM.
Allergen uptake by hmoDCs and inhibition assays
Immature hmoDCs were cultured with 50 mg/mL N, P, PM, and PM OX
equally labeled with Alexa Fluor 488 C5 maleimide (Invitrogen,
Carlsbad, Calif) at different times at 378C. Cells were washed with cold
PBS, 2 mmol/L EDTA, and 0.5% BSA 2 times before surface staining with
anti-human HLA-DR–FITC and analyzed by using flow cytometry and
confocal microscopy. For inhibition assays, cells were preincubated with
cytochalasin D (5 mmol/L; Sigma, St Louis, Mo), chlorpromazine
(7.5 mg/mL, Sigma), PAO (2 mmol/L, Sigma), EDTA (2 mmol/L, Sigma),
DMSO as a vehicle control, anti-humanCD206mAb (10mg/mL, BioLegend),
anti-human CD209mAb (20mg/mL, R&D Systems), or an isotype control for
30minutes at 378Cor with anti-humanDectin-2 (20mg/mL, R&DSystems) or
a corresponding isotype control for 2 hours. Afterward, labeled or unlabeled
N, P, and PMwere added to the cells and incubated for 30 minutes (for uptake
assays) or 18 hours (for cytokine quantification). For the NF-kB inhibition
assays, cells were incubated with BAY 117082 (5 mmol/L, Sigma) or
DMSO as a vehicle control for 30minutes before PM stimulation. For all these
assays, titration of dose and time responses was optimized previously.
Cytokine quantification
Cytokine quantification in cell-free supernatants was performed by means
of ELISA with specific commercial kits, according to the manufacturer’s
protocols for IL-4, IL-5, IL-6, IL-10, IFN-g (BD PharMingen), and IL-17
(R&D Systems). The ELISA reader (Bio-Rad Laboratories, Hercules, Calif)
was used for OD measurement.
Coculture experiments and proliferation assays
Naive CD41 T cells were purified from PBMCs by using the Naive CD41
T Cell Isolation Kit (Miltenyi Biotec). The obtained negative fraction was
further purified with anti-human CD14 and anti-human CD45RO coupled to
microbeads (Miltenyi Biotec) by means of negative selection to reach greater
than 99% purity. N-, P-, and PM-treated hmoDCs were cocultured with
purified allogeneic naive CD41 T cells at a 1:5 ratio for 6 days, as
previously described.E3 As controls, naive CD41 T cells supplemented with
IL-2 (100 U/mL, PeproTech) were cultured alone in complete RPMI. Purified
naive CD41 T cells were labeled with carboxyfluorescein succinimidyl ester
(CFSE) (ThermoFisher Scientific, Madrid, Spain) for 5 minutes at 48C and
washed twice with medium. After 6 days of coculture with N-, P-, or
PM-stimulated hmoDCs, cells were harvested and stained with anti-human
CD4-PerCP, and proliferation was determined based on CFSE dilution using
flow cytometry. PD-L1 inhibition assays were performed by adding
anti-human PD-L1 (10 mg/mL) to cocultures. After 6 days, cells were
harvested for further assays and cytokine quantification.
CFSE-labeled PBMCs from allergic donors were cultured with N, P, or PM
(50 mg/mL) for 5 days. Proliferative responses and cytokine levels in cell-free
culture supernatants were determined bymeans of flow cytometry and ELISA,
respectively.
Treg cell suppression assay
CD41CD25highCD1272FOXP31 Treg cells induced by allogeneic N-, P-,
or PM-stimulated hmoDCs were enriched with anti-human CD25 microbeads
(Miltenyi Biotec), according to themanufacturer’s instructions. The unlabeled
enriched fraction of CD41CD25highCD1272FOXP31 Treg cells was mixed
with CFSE-labeled autologous PBMCs (responder cells) at different ratiosand stimulated with plate-bound anti-human CD3 antibody (1 mg/mL,
clone OKT3; eBioscience, San Diego, Calif) and soluble anti-human CD28
(1 mg/mL, clone CD28.6; eBioscience) for 5 days. For control purposes,
CFSE-labeled PBMCs were cultured alone with or without stimulation.
Proliferation of CD41 T cells was determined by using CFSE dilution with
flow cytometry.
ELISpot identification of allergen-specific IFN-g–,
IL-10–, and IL-4–producing T cells after expansion
by mean of ex vivo immunization with N-, P-, or
PM-activated autologous hmoDCs
Immature hmoDCs were stimulated with 100 mg/mL of N, P, or PM
extracts for 8 hours and subsequently matured for 18 hours with 1 mg/mL
peptidoglycan. Matured hmoDCs were restimulated for an additional 6 hours
with N, P, or PM and irradiated (3000 rad). These cells were cocultured with
autologousmonocyte-depleted PBMCs in the presence of IL-7 (20 U/mL) and
supplemented at day 5 with IL-2 (10 U/mL). After 7 days, the same protocol
was carried out in the sameway to complete a total of 3 ex vivo immunizations
with autologous N-, P-, or PM-treated hmoDCs. Seven days after the last
immunization, expanded allergen-specific T cells producing IFN-g, IL-10,
and IL-4 were identified by using the ELISpot assay. Briefly, 96-well high-
affinity plates (Millipore, Temecula, Calif) were coated with 10 mg/mL of
capture mAb against IFN-g, IL-10, or IL-4 (Millipore) at 48C for 18 hours.
A total of 25,000 expanded allergen-specific T cells were added to each
well and stimulated with 25,000 autologous PBMCs, which were previously
incubated with 100 mg/mL of the allergen, for 18 hours in a 5% CO2
atmosphere at 378C and processed as previously described.E4 Briefly,
biotinylated detection antibody was added and incubated for 2 hours at
room temperature. Plates were washed, incubated with alkaline phosphatase
streptavidin for 1 hour in the dark at room temperature, and developed with
SIGMAFAST BCIP/NBT (Sigma). The reaction was stopped by rinsing the
plates with PBS-Tween (0.05%) and washed with distilled water. Each well
was then examined for positive dots. The number of dots in each well was
counted automatically with an ELISpot reader system (Immunospot Reader
System). The obtained spots represent the number of cells that secreted the
cytokine of interest (spot-forming cells). Each testing condition is assayed
separately and compared with the negative control counts (spot-forming cells
without antigenic stimulus). More than 50 spot-forming cells per well and a
value at least 3 times greater than the background was considered a positive
result.
Immunoblot analysis
Freshly isolated hmoDCs were treated with N, P, and PM extracts at
50 mg/mL. After 15 minutes at 378C, cells were harvested and lysed with PBS
and 0.1% Triton X-100 supplemented with protease inhibitors (1 mmol/L
phenylmethylsulfonyl fluoride and 1 mg/mL aprotinin and leupeptin; Roche,
Mannheim, Germany) for 30 minutes at 48C with vortexing every 10 minutes.
Lysates were centrifuged for 15 minutes at 10,000g and 48C, and supernatants
were collected for protein quantification with Micro BCA Kit (Pierce,
Rockford, Ill). Thirty micrograms of total protein from cell lysates was
separated by means of SDS-PAGE and transferred onto a nitrocellulose
membrane (Bio-Rad Laboratories). The membrane was incubated with the
indicated antibodies used as follows: phopho-NF-kB p65, total-NF-kB p65
(1:1000; Cell Signaling, Danvers, Mass), and b-actin (1:1000, Sigma) as
primary antibodies and goat anti-rabbit (1/3000, Bio-Rad Laboratories) or
goat anti-mouse (1:2500, Pierce) conjugated with horseradish peroxidase as
a secondary antibody. Reactive bands were visualized with the ECL
chemiluminescence system (Bio-Rad Laboratories). The OD of the reactive
bands was quantified with Fujifilm multigauge software, and values were
expressed relative to the b-actin loading control.
RNA extraction, cDNA synthesis, and quantitative
real-time RT-PCR
RNA was isolated from harvested cells by using an RNeasy Mini Kit
(Qiagen, Hilden, Germany). According to the manufacturer’s instructions.
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Japan). Real-time quantitative PCR was performed on cDNA by using
FastStart Universal SYBR Green Master (Rox; Roche). The sequences of
the used pair primers were as follows: PD-L1 (forward, AAGATGAGGATA
TTTGCTGTCTTTATATTC; reverse, GTCCTTGGGAACCGTGACAGT),
IDO (forward, AGAAGTGGGCTTTGCTCTGC; reverse, TGGCAAGACCT
TACGGACATCTC), RALDH1 (forward, CTGCCGGGAAAAGCAATCT;
reverse, AAATTCAACAGCATTGTCCAAGTC), RALDH2 (forward, AG
GGCAGTTCTTGCAACCAT; reverse, GCGTAATATCGAAAGGTTTTGA
TGA), SOCS1 (forward, CCCTGGTTGTTGTAGCAGCTT; reverse, CAA
CCCCTGGTTTGTGCAA) SOCS3 (forward, CCTCAGCATCTCTGTCGG
AAGA; reverse, GCATCGTACTGGTCCAGGAACT), and elongation factor
1a (EF1a; forward, CTGAACCATCCAAT; reverse, GCCGTGTGGCAATC-
CAAT). Samples were run on a real-time PCR system (ABI Prism 7900 HT;
Applied Biosystems, Foster City, Calif). Data were normalized to EF1a and
displayed as 22DCT values multiplied by 104, with D cycle threshold (DCT)
defined as the difference between the CT value for the gene of interest and
EF1a.
Immunization of mice with N, P, PM, or PM OX;
quantification of induced serum allergen-specific
IgG2a and IgE levels; and cytokine profiles of
splenocytes stimulated in vitro with N
BALB/c female mice (6 weeks old) were immunized 3 times with 20 mg
(200 mL at 100 mg/mL) of N, P, PM, or PM OX by means of subcutaneous
injection every 15 days and killed 7 days after the last immunization. Serum
specific IgE and IgG2a reactivities to N induced with each treatment were
determined by means of ELISA. Spleens were used to prepare single-cell
suspensions according to conventional protocols. The presence of splenicCD41CD25highFOXP31 Treg cells in the different immunized mice was
quantified, as described above. Splenocytes were stimulated in vitro with N,
and cytokine (IL-4 and IL-10) production was measured by using Multiplex
Cytometric kits (eBioscience) in 48-hour culture supernatants. Animal
experiments were approved by the Ethics Committee of Hospital Clınico
San Carlos and performed in accordance with the Spanish national and
international/European Union legislation regulated by D.C.86/609/CEE; RD
1201/2005.
Statistical analyses
In all experiments data represent means 6 SEMs of the indicated
parameters. Statistical differences were determined by using the paired or
unpaired Student t test or the Wilcoxon test, as indicated in each figure by
using Prism software 6.0 (GraphPad Software, La Jolla, Calif). Significance
is indicated in each figure.
FIG E1. Chemical strategy to generate allergoids conjugated to nonoxidized mannan. Taking advantage of
the presence of lysine residues in the purified mannan preparation, native grass pollen P pratense allergen
extract was polymerized and conjugated with mannan in a single step with glutaraldehyde to generated
glutaraldehyde-polymerized allergoids conjugated to nonoxidized mannan (PM). Part of the same native
allergen extract was also subjected to polymerization without mannan to obtain a mannan-free
glutaraldehyde-polymerized allergoids (P) or used without polymerization as native allergen extract (N).
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FIG E2. Phenotypic characterization of hmoDCs and comparison of different fluorescent probes for extract
labeling. A, Representative histograms for the phenotype of immature hmoDCs. Freshly differentiated
hmoDCs were analyzed by using flow cytometry for HLA-DR, CD86, CD83, CD80, CD206, CD209, and
Dectin-2 expression (open histograms). Shaded histograms represent the reactivity of fluorochrome-
matched isotype controls. B, Fluorescence intensity of different concentrations of N, P, and PM extracts
labeled with thiol-reactive Alexa Fluor 488 (left) or amine-reactive Alexa Fluor 488 (right).
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FIG E3. PD-L1 mRNA expression is increased in PM-treated hmoDCs. mRNA expression levels of PD-L1,
IDO, RALDH1, RALDH2, SOCS1, and SOCS3 genes in hmoDCs treated with N, P, or PM. Arbitrary units (A.u.)
are 22DCT values multiplied by 104, with DCT defined as the difference between the CT value for the gene
of interest and EF1a. Data are means 6 SEMs (n 5 4). Statistical significance was determined with the
Student t test: *P < .05.
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FIG E4. Representative dot plot of proliferating CFSE-labeled naive CD41 T cells after 5 days of
coculture with N-, P-, or PM-activated allogeneic hmoDCs. The frequency of proliferating cells is displayed
(n 5 6 independent experiments).
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FIG E5. Suppression capacity of FOXP31 Treg cells induced by allogeneic N-, P-, and PM-treated hmoDCs.
Proliferation of CFSE-labeled PBMCs gated on CD41 cells after 5 days of coculture with autologous
purified CD41CD25highCD1272FOXP31 Treg cells induced by N-treated (A), P-treated (B), and PM-treated
(C) allogeneic hmoDCs is shown. Histograms show the percentage of proliferating responder PBMCs
stimulated with plate-bound anti-CD3 and soluble anti-CD28 for each assayed condition at different Treg
cell/responder PBMC ratios. The graph shows data from 3 independent experiments.
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FIG E6. One-dimensional proton nuclear magnetic resonance spectrum of samples before and after
oxidation (blue and red traces, respectively). The aliphatic part of the protein profile (from 0-3 ppm in the
spectrum) is maintained after oxidation, whereas the carbohydrate-anomeric zone (from 3.5-5.5 ppm) is
significantly perturbed. The signature of formic acid coming from the oxidation of terminal mannose
residues is also observable (peak at 8.4 ppm).
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FIG E7. Gating strategy used to identify and compare the CD25highFOXP3 Treg cell population in spleens
from mice immunized with N, P, or PM. A representative histogram for CD25 and FOXP3 from mice
immunized with PM is shown. In the CD25 histogram a shoulder for the gated population of cells with
CD25high expression is clearly visible. All these cells also express high FOXP3 levels.
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TABLE E1. Clinical features of the patients with grass pollen allergy included in the study
Patient no. Age (y) Sex Allergic to Symptoms SPT response (mm2) with N P pratense Other pollen allergies
1 70 Male Grasses RC 40.69 Olea species
2 29 Female Grasses RC-A 12.56 Olea species, Cupressus species
3 27 Male Grasses RC-A 18.09 Platanus species
4 78 Female Grasses RC 24.62 Olea species
5 54 Female Grasses RC 32.15 Olea species
6 63 Female Grasses RC-A 40.69 Cupressus species
7 25 Female Grasses RC 24.62
8 33 Female Grasses RC-A 24.62 Olea species, Cupressus species
9 24 Male Grasses RC 113.04 Olea species, Cupressus species
10 11 Male Grasses RC 72.35 Olea species
11 46 Male Grasses RC 18.09
12 35 Female Grasses RC 50.24
A, Asthma; RC, rhinoconjunctivitis.
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